IL6 and neuroblastic tumor: The analysis of clinicopathological factors with the serum levels of pro-inflammatory cytokines evaluated in this study showed a significant association (p = 0.022) between IL-6 levels and tumor differentiation; this is observed in Table A2, where 44.4% of patients with low serum levels of this cytokine presented partially differentiated neuroblastic tumors.